Comparison · NCT01239342-sae
MK2206 vs Everolimus: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MK2206 vs Everolimus: serious adverse events. Trial comparisons, record NCT01239342-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01239342-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.241 | 0.122 | 0.421 | wilson | |
| Risk in group 2 | 0.143 | 0.0401 | 0.399 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0985 | -0.184 | 0.306 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.69 | 0.402 | 7.1 | log | |
| Odds ratio, group 1 over group 2 | 1.91 | 0.341 | 10.7 | log | |
| Number needed to harm, for one more participant with a serious adverse event on MK2206 than on Everolimus | 10.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MK2206 | Akt inhibitor MK2206 200 mg orally once weekly, courses repeat every 4 weeks. | 7 | 29 | EG000 |
| Group 2 | Everolimus | Everolimus 10 mg orally once daily, courses repeat every 4 weeks. | 2 | 14 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events collected through each 28 day course, and reporting for events that occur within 30 Days of the last dose of the investigational agent.
Source ClinicalTrials.gov
Trial
- Title
- Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
- NCT number
- NCT01239342
- Phases
- PHASE2
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Akt Inhibitor MK2206, Everolimus, Laboratory Biomarker Analysis
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2017-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01239342?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01239342-sae